Addex Therapeutics is a biotechnology business based in the US. Addex Therapeutics shares (ADXN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.38 – a decrease of 10% over the previous week. Addex Therapeutics employs 23 staff and has a trailing 12-month revenue of around $863,232.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.38 |
|---|---|
| 52-week range | $5.00 - $27.90 |
| 50-day moving average | $10.25 |
| 200-day moving average | $10.54 |
| Wall St. target price | $30.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-19.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.97 from 2024-11-19
| 1 week (2024-11-15) | -1.12% |
|---|---|
| 1 month (2024-10-21) | -22.62% |
| 3 months (2024-08-21) | 4.87% |
| 6 months (2024-05-21) | -8.55% |
| 1 year (2023-11-21) | 32.83% |
|---|---|
| 2 years (2022-11-21) | -51.40% |
| 3 years (2021-11-19) | 142.402 |
| 5 years (2019-11-18) | N/A |
| Revenue TTM | $863,232 |
|---|---|
| Gross profit TTM | $1.4 million |
| Return on assets TTM | -61.71% |
| Return on equity TTM | -126.29% |
| Profit margin | 500.17% |
| Book value | $0.13 |
| Market Capitalization | $9.4 million |
TTM: trailing 12 months
We're not expecting Addex Therapeutics to pay a dividend over the next 12 months.
Addex Therapeutics's shares were split on a 1:20 basis on 22 October 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Addex Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Addex Therapeutics shares which in turn could have impacted Addex Therapeutics's share price.
Over the last 12 months, Addex Therapeutics's shares have ranged in value from as little as $5 up to $27.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Addex Therapeutics's is 1.874. This would suggest that Addex Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.